

December 2, 2019



iBio to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) announced today that management will present an update on the Company's business at the first annual [BioTuesdays Pre-JPM Virtual Conference](#) on Tuesday, December 10, 2019 at 11:30 a.m. Eastern Time.

The live and archived presentation can be accessed [here](#).

About iBio, Inc.

iBio, Inc., is a global leader in plant-based biologics manufacturing. Its FastPharming™ System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company's wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming-based Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas. iBio CDMO also enables innovators to use FastPharming technologies for insourced manufacturing via its Factory Solutions "design-and-build" services. iBio is also developing its own proprietary products which include its lead asset, IBIO-100, for the treatment of fibrotic diseases. For more information, visit www.ibioinc.com.

Cautionary Statement Regarding Forward Looking-Statements

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contact:

Stephen Kilmer
Investor Relations
(646) 274-3580
skilmer@ibioinc.com



Source: iBio, Inc.